Tag: 30-month stay
30-Month Stay: How Litigation Delays Generic Drug Approval
Finnegan O'Sullivan Jan 25 14The 30-month stay under the Hatch-Waxman Act delays generic drug approval by freezing FDA approval during patent litigation. While designed to balance innovation and access, it's now often used to extend monopolies, costing patients billions annually.
More Detail